Trial Profile
An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Daxibotulinumtoxin A (Primary)
- Indications Glabellar lines
- Focus Adverse reactions; Registrational
- Acronyms SAKURA-3
- Sponsors Revance Therapeutics
- 10 Oct 2022 According to Revance Therapeutics media release, subgroup analysis data from this trial will be presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting 2022.
- 19 Sep 2022 Results published in Revance Therapeutics Media Release
- 19 Sep 2022 According to Revance Therapeutics media release, post-hoc analysis of patients in the Phase 2a forehead line (FHL) study and the SAKURA open-label safety (OLS) study as well as the efficacy and safety of DAXXIFY analyzed by age and race based on a subgroup analysis of the SAKURA glabellar lines clinical trials was published in Aesthetic Surgery Journal.